Agilent to Acquire North American CDMO BIOVECTRA
Agilent Technologies Inc. (NYSE: A) has announced a $925 million acquisition of BIOVECTRA, a leading specialized contract development and manufacturing organization (CDMO) based in Canada. This strategic move expands Agilent's end-to-end biopharma solutions in three key areas:
1. Portfolio expansion: Adding sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle formulation.
2. Rapidly growing modalities: Gaining expertise in antibody drug conjugates, highly potent active pharmaceutical ingredients, and GLP-1.
3. Gene editing capabilities: Combining BIOVECTRA's biologics expertise with Agilent's gRNA knowledge.
BIOVECTRA reported $113 million in revenue for 2023 and expects double-digit growth in 2024. The acquisition is expected to close before 2025 and will be $0.05 dilutive to Agilent's non-GAAP EPS in the first full year after closing.
Agilent Technologies Inc. (NYSE: A) ha annunciato un
1. Espansione del portafoglio: Aggiunta di servizi di riempimento e finitura sterili, capacità di pDNA e mRNA, e formulazione di nanoparticelle lipidiche.
2. Modalità in rapida crescita: Acquisizione di competenze nei coniugati di farmaci a base di anticorpi, ingredienti farmaceutici attivi altamente potenti e GLP-1.
3. Competenze di editing genetico: Combinazione dell'expertise biologica di BIOVECTRA con la conoscenza di gRNA di Agilent.
BIOVECTRA ha riportato 113 milioni di dollari di fatturato per il 2023 e prevede una crescita a due cifre nel 2024. Si prevede che l'acquisizione si chiuderà prima del 2025 e avrà un impatto diluitivo di 0,05 dollari sull'EPS non-GAAP di Agilent nel primo anno completo dopo la chiusura.
Agilent Technologies Inc. (NYSE: A) ha anunciado una
1. Ampliación de cartera: Incorporación de servicios de llenado y terminación estériles, capacidades de pDNA y mRNA, y formulación de nanopartículas lipídicas.
2. Modalidades de rápido crecimiento: Adquisición de experiencia en conjugados de fármacos basados en anticuerpos, ingredientes farmacéuticos activos altamente potentes y GLP-1.
3. Capacidades de edición genética: Combinación de la experiencia biológica de BIOVECTRA con el conocimiento de gRNA de Agilent.
BIOVECTRA reportó 113 millones de dólares en ingresos para 2023 y espera un crecimiento de dos dígitos en 2024. Se espera que la adquisición se cierre antes de 2025 y tendrá un impacto dilutivo de 0,05 dólares en el EPS no-GAAP de Agilent en el primer año completo después del cierre.
Agilent Technologies Inc. (NYSE: A)는 캐나다에 본사를 둔 선도적인 계약 개발 및 제조 기관(CDMO)인 BIOVECTRA를 9억 2500만 달러에 인수한다고 발표했습니다. 이 전략적 움직임은 Agilent의 생명공학 제약 솔루션을 세 가지 주요 분야로 확장합니다:
1. 포트폴리오 확장: 멸균 충전 및 마감 서비스, pDNA 및 mRNA 능력, 및 지질 나노 입자 제형 추가.
2. 급성장하는 양상: 항체 약물 접합체, 고활성 의약품 성분 및 GLP-1에 대한 전문성 확보.
3. 유전자 편집 능력: BIOVECTRA의 생물학적 전문성과 Agilent의 gRNA 지식 결합.
BIOVECTRA는 2023년 매출 1억 1300만 달러를 기록했으며, 2024년에는 두 자릿수 성장을 기대하고 있습니다. 인수는 2025년 이전에 종료될 것으로 예상되며, 종료 후 첫 번째 전체 연도에 Agilent의 비-GAAP EPS에 0.05달러의 희석 효과가 있을 것입니다.
Agilent Technologies Inc. (NYSE: A) a annoncé une acquisition de 925 millions de dollars de BIOVECTRA, une organisation de développement et de fabrication sous contrat (CDMO) spécialisée et leader, basée au Canada. Ce mouvement stratégique élargit les solutions biopharmaceutiques d'Agilent dans trois domaines clés :
1. Extension du portefeuille: Ajout de services de remplissage et de finition stériles, de capacités en pDNA et mRNA, et de formulation de nanoparticules lipidiques.
2. Modalités en forte croissance: Acquisition d'expertise en conjugués de médicaments anticorps, en ingrédients pharmaceutiques actifs hautement puissants et en GLP-1.
3. Capacités d'édition génétique: Combinaison de l'expertise biologique de BIOVECTRA avec les connaissances en gRNA d'Agilent.
BIOVECTRA a rapporté 113 millions de dollars de revenus en 2023 et prévoit une croissance à deux chiffres en 2024. L'acquisition devrait être finalisée avant 2025 et aura un impact dilutif de 0,05 dollar sur le bénéfice par action non-GAAP d'Agilent au cours de la première année complète suivant la clôture.
Agilent Technologies Inc. (NYSE: A) hat eine Akquisition in Höhe von 925 Millionen Dollar von BIOVECTRA angekündigt, einem führenden spezialisierten Vertragsentwicklungs- und -herstellungsunternehmen (CDMO) mit Sitz in Kanada. Dieser strategische Schritt erweitert Agilents End-to-End-Biopharma-Lösungen in drei Schlüsselbereichen:
1. Portfolioerweiterung: Hinzufügen von sterilen Abfüll- und Fertigstellungsdiensten, pDNA- und mRNA-Fähigkeiten sowie Lipid-Nanopartikel-Formulierung.
2. Schnell wachsende Modalitäten: Erwerb von Fachwissen in Antikörper-Arzneimittel-Konjugaten, hochpotenten Arzneimittelinhaltsstoffen und GLP-1.
3. Gene Editing Fähigkeiten: Kombination von BIOVECTRAs biologischer Expertise mit Agilents gRNA-Kenntnissen.
BIOVECTRA erzielte 113 Millionen Dollar Umsatz im Jahr 2023 und erwartet im Jahr 2024 ein zweistelliges Wachstum. Die Akquisition wird voraussichtlich vor 2025 abgeschlossen sein und wird im ersten vollen Jahr nach dem Abschluss 0,05 Dollar auf Agilents non-GAAP EPS auswirken.
- Acquisition expands Agilent's biopharma solutions portfolio
- Gains expertise in rapidly growing modalities like ADCs and HPAPIs
- Enhances gene editing capabilities
- BIOVECTRA expects double-digit revenue growth in 2024
- Acquisition strengthens Agilent's position in the CDMO market
- Acquisition expected to be $0.05 dilutive to non-GAAP EPS in first full year
- Significant acquisition cost of $925 million
Financial Implications: The acquisition of BIOVECTRA for
Technological Synergy: The acquisition brings together complementary technologies and expertise. BIOVECTRA’s capabilities in biologics and highly potent active pharmaceutical ingredients (HPAPIs) are impressive. When paired with Agilent’s proficiency in oligonucleotides and CRISPR therapeutics, this could lead to enhanced and more integrated solutions for biopharma clients. This synergy is likely to accelerate innovation and improve efficiencies in drug discovery, development and manufacturing. The added capabilities in sterile fill-finish services and lipid nanoparticle formulation also position Agilent strongly in emerging therapeutic modalities.
Market Position and Growth: This acquisition strategically positions Agilent in rapidly growing biopharma segments such as antibody drug conjugates (ADCs) and GLP-1, which are seeing increased demand. BIOVECTRA’s established presence in North America and Europe expands Agilent’s market reach and customer base. This move can be seen as a strategic expansion into high-growth areas, potentially increasing Agilent’s market share and competitive edge. Furthermore, BIOVECTRA’s expected double-digit revenue growth in 2024 presents a promising outlook for contributing to Agilent’s top-line growth.
Expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing
A BIOVECTRA manufacturing facility (Photo: Business Wire)
Based in
The acquisition builds on Agilent’s CDMO specialization in oligonucleotides and CRISPR therapeutics in three key areas:
- Expands portfolio of services. BIOVECTRA offers sterile fill-finish services, pDNA and mRNA capabilities, and lipid nanoparticle (LNP) formulation.
- Adds rapidly growing modalities. BIOVECTRA brings expertise in fast-growing segments, including antibody drug conjugates (ADCs), highly potent active pharmaceutical ingredients (HPAPIs), and GLP-1.
- Brings world-class capabilities to support gene editing. BIOVECTRA’s capabilities in biologics combined with Agilent’s expertise in gRNA will provide customers with a single source for gene-editing technology.
Both BIOVECTRA and Agilent are fully integrated CDMOs with state-of-the-art facilities that follow current Good Manufacturing Practices (cGMP), a high standard for methods, facilities, and controls used in manufacturing, processing, and packaging of active pharmaceutical ingredients.
“We look forward to welcoming BIOVECTRA to Agilent,” said Agilent President and CEO Padraig McDonnell. “The company has an outstanding record of innovation, and its employees share our commitment to providing integrated biopharma solutions that continuously deliver more value to customers.”
McDonnell continued: “Plus, BIOVECTRA’s manufacturing capabilities further expand Agilent’s end-to-end biopharma offerings into new growth vectors, including workflows that seamlessly integrate analytical instrumentation, consumables, and a wide range of lab services.”
BIOVECTRA supports early-stage clinical development to large-scale commercial manufacturing. The company currently serves biotech and pharmaceutical companies in
“BIOVECTRA is excited to join Agilent, a company whose dedication to people and customers is very much aligned with ours,” said Oliver Technow, CEO of BIOVECTRA. “BIOVECTRA has dedicated nearly 55 years to the relentless pursuit of helping our customers solve complex problems that improve patients’ lives. This synergistic pairing of our capabilities with Agilent’s will further enhance the value we can offer to our customers.”
BIOVECTRA delivered
The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close before 2025. Upon close, BIOVECTRA will become part of the Agilent Diagnostics and Genomics Group.
About BIOVECTRA
BIOVECTRA (www.biovectra.com) is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, lipids, pDNA, mRNA and LNP manufacturing and fill finish for drug products. Flexibility, creativity, process optimization and compliance are at the heart of our method. With nearly 55 years of experience and cGMP facilities in
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of
Forward Looking Statements
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the capabilities the acquisition brings and the assets’ future uses. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent’s customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; unforeseen changes in the currency markets; customer purchasing decisions and timing; and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; the ability to meet and achieve the benefits of its cost-reduction goals and otherwise successfully adapt its cost structures to continuing changes in business conditions; ongoing competitive, pricing and gross-margin pressures; the risk that its cost-cutting initiatives will impair its ability to develop products and remain competitive and to operate effectively; the impact of geopolitical uncertainties and global economic conditions on its operations, its markets and its ability to conduct business; the ability to improve asset performance to adapt to changes in demand; the ability of its supply chain to adapt to changes in demand; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent’s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the fiscal quarter ended April 30, 2024. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722078870/en/
Investor Contact
Parmeet Ahuja
+1 408 345 8948
parmeet_ahuja@agilent.com
Media Contact
Sarah Litton
+1 408 361 0405
sarah.litton@agilent.com
Source: Agilent Technologies Inc.
FAQ
What is the value of Agilent's acquisition of BIOVECTRA?
How will the BIOVECTRA acquisition impact Agilent's earnings?
What are the key areas of expansion for Agilent through this acquisition?
When is the BIOVECTRA acquisition expected to close?
What was BIOVECTRA's revenue in 2023 and what is its growth projection for 2024?
